These studies and others reported in vivo evidence that CGRP can protect against hypertension and the vasoconstrictor effects of hypertensive agents including angiotensin-II (AngII) (Itabashi et al., 1988; Fujioka et al., 1991), noradrenaline (Fujioka et al., 1991), deoxycorticosterone-salt (Supowit et al., 1997; Supowit et al., 2005), and the nitric oxide synthase (NOS) inhibitor L-NAME (Gardiner et al., 1991; Gangula et al., 1997), making progress toward understanding the mechanism of action of CGRP (Kumar et al., 2019a). This evidence concerns the gene AGT and hypertensive disorder.